Creative Biolabs develops and commercializes a full range of integrated innovative services that are based on phage display technology. We have ...
Creative Biolabs can offer advanced protein engineering platform for your specific project, including high-scale expression, crystallization and characterization...
Creative Biolabs has established custom membrane protein and membrane protein antibody production platforms for antibody discovery...
Creative Biolabs provides a full range of services based on our matured hybridoma platform. Our featured services involve the custom monoclonal antibody production, from ...
Creative Biolabs antibody cysteine modification platform has the unprecedented ability to produce antibodies introduced free cysteine without disrupting any antigen-targeting capacity, stability or homogeneity, which cannot be otherwise produced in any other platform. Advantages include quality, stability, purity, rapidly delivery as well as reduced production and development cost. This service has a wide application including but not limited to molecular imaging, antibody-drug conjugations (ADCs) and diagnostics.
Modification of proteins by the covalent attachment of payloads has gained prominence in the development of therapeutic proteins. In the past decade, many novel site-specific, bio-orthogonal reactions that enable precise and controlled modification of proteins have been reported. Comparing with the primary amines of lysines, it takes more advantages to choose sulfhydryls of cysteines serve as conjugation sites. Because this amino acid is less abundant and forms conserved disulfide bridges in antibodies to eliminate the risk of leading to steric hindrance of target recognition, we use both conventional modification methods and novel precise modification at engineered C- or N-terminal free cysteines of antibodies, such as site-specific mutagenesis and traceless cleavable linkers.
Fig. 1 Construction of a traceless chemically defined tumor-vascular targeting antibody-drug conjugate based on disulfide linkage. (Bernardes et al. 2013)
Fig. 2 Massa et al. (2014)
We guarantee any antibody cysteine modification (over 95% purity) with excellent homogeneity and antigen-binding properties.
Expertise knowledge and rich experience in site-specific modification and conjugation;
A comprehensive system of both conventional and modern novel methods and technologies for biomodification and conjugation;
Professional computational modelling and computer analysis design for site-specific modification residues selection.
Quality Controls Measures
The following quality control measures are employed to create the highest quality monoclonal antibodies commercially available: ELISA against the antigen, HPLC.
Bernardes, G. J., Steiner, M., Hartmann, I., Neri, D. and Casi, G. (2013) 'Site-specific chemical modification of antibody fragments using traceless cleavable linkers', Nature protocols, 8(11), 2079-2089.
Massa, S., Xavier, C., De Vos, J., Caveliers, V., Lahoutte, T., Muyldermans, S. and Devoogdt, N. (2014) 'Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging', Bioconjugate chemistry, 25(5), 979-988.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us